Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. (AIMLF) delivers cutting-edge artificial intelligence and machine learning solutions for digital health transformation. This page provides investors and industry professionals with essential updates about the company's strategic initiatives, regulatory milestones, and technological advancements.
Access comprehensive coverage of AIMLF's partnerships with Health Gauge Inc., AI Rx Inc., and other key players in healthcare technology. Track developments stemming from acquisitions like Quantum Sciences Ltd. and stay informed about operational updates across neural networks, cloud computing integrations, and precision healthcare platforms.
Key updates include: earnings reports, strategic investment announcements, regulatory filings, and leadership changes. Our curated news collection ensures you receive accurate information about the company's progress in developing AI-powered diagnostic tools and patient engagement systems.
Bookmark this page for verified updates about AIMLF's role in advancing machine learning applications for cardiovascular monitoring, neurodegenerative disorder management, and metabolic health solutions. Visit regularly to maintain current awareness of this innovator's evolving position in digital healthcare markets.
AI/ML Innovations has launched The Neural Net Store, an online commercial portal offering flexible, affordable access to its AI-driven healthcare solutions. The NNStore features products like the Follow Your Heart suite for Blood Pressure measurement and a Long ECG Neural Network analytical tool. Users can access these tools via downloadable APIs for integration into third-party applications or through a cloud-based Neural Net Service (NNaaS). This service is designed to eliminate barriers in adopting AI solutions in healthcare, offering options for both infrequent and frequent users, including developers and healthcare organizations. The introduction of the NNStore aims to facilitate easier implementation of AI technologies, thereby driving innovation in healthcare.
AI/ML Innovations has announced an agreement with Moonshot, appointing Paul Duffy as CEO. The contractual agreement includes a $125,000 signing bonus in shares, another $125,000 in shares on the second anniversary, and annual retention fees of $250,000 and $300,000 over two years, payable quarterly in shares. Additionally, Moonshot receives options to purchase up to 1.5 million shares at $0.20 each, vesting in three installments contingent on specific milestones. The issuance of shares and options requires Canadian Securities Exchange approval.
AI/ML Innovations has announced the formation of a new subsidiary, NeuralCloud Solutions. This subsidiary aims to capitalize on the convergence of the global smart sensor market and the digital health industry by monetizing recently acquired assets from Naiad Labs. The smart sensors market, valued at USD 52.4 billion in 2023, is expected to reach USD 160.3 billion by 2030. The global digital health market, valued at USD 217 billion in 2022, is projected to reach USD 1,592 billion by 2032. NeuralCloud will focus on delivering personalized health intelligence through advanced sensor technologies and AI. Esmat Naikyar has been appointed as President and Chief Product Officer of NeuralCloud.
AI/ML Innovations Inc. introduces its proprietary Long ECG Neural Net technology, reducing labeling of long ECGs from days to minutes. The technology offers high accuracy, depth, and insight into cardiac data, catering to cardiologists, researchers, and pharmaceuticals. With over 100 million ECGs performed annually in the USA, this innovation aims to revolutionize ECG analysis, potentially detecting and predicting cardiovascular diseases. The company plans for FDA approval, online access, and accelerating diagnoses and predictions.
AI/ML Innovations Inc. has entered into a binding Letter of Intent to acquire strategic healthcare assets from Naiad Labs Inc., including a Long ECG Neural Net that reduces reading time to under 5 minutes. The acquisition involves issuing 6,700,000 Common Shares valued at $469,000 to Naiad, creating a new operating subsidiary, paying a streaming royalty, and granting stock options to Naiad management. The deal is non-arm's length due to AIML's Interim CPO's association with Naiad Labs. The closing is subject to due diligence and regulatory approvals, aiming for completion by May 30, 2024.
FAQ
What is the current stock price of AI / ML Innovations (AIMLF)?
What is the market cap of AI / ML Innovations (AIMLF)?
